{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:42:18Z","timestamp":1793400138999,"version":"4.5.0"},"reference-count":31,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In follicular lymphoma (FL), detection of bone marrow (BM) involvement (BMI) by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)\/computed tomography (CT) improves the accuracy of staging vs BM biopsy (BMB) alone. Our objective was to determine the diagnostic utility of PET for BMI FL and the prognostic value of BMI by PET (positive PET result [PET+]). Records of patients (2002-2016) with PET and BMB at the time of initial treatment were reviewed. BMI was identified by positive BMB result (BMB+) and\/or unifocal or multifocal BM FDG uptake on blindly reviewed PET scans with no corresponding CT abnormality (PET+). Among 261 patients, BMI was diagnosed in 78 patients (29.9%) by PET+, in 81 patients (31.0%) by BMB+, and in 113 patients (43.3%) by either PET+ or BMB+. PET+ upstaged 24 patients to stage IV, including 10 from stages I or II to stage IV. Median duration of follow-up was 6.0 years (range, 0-16.6 years). In univariate analysis, a high Follicular Lymphoma International Prognosis Index (FLIPI) score, PET+, and BMB+ correlated with shorter progression-free survival (PFS; all P \u2264 .03), and high FLIPI, PET+, and combined PET+ and BMB+ with shorter overall survival (OS; all P \u2264 .01). In multivariate analysis, PET+ was the only independent predictor of PFS, whereas high FLIPI score and PET+ predicted OS (P \u2264 .03). Combined PET and BMB identify BMI more accurately than either BMB or PET alone, but BMB rarely adds critical information. For patients initiating treatment of FL, identification of BMI by PET is predictive of PFS and OS.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020001579","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T15:40:39Z","timestamp":1588088439000},"page":"1812-1823","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":43,"title":["Baseline FDG-PET\/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information"],"prefix":"10.1182","volume":"4","author":[{"given":"Reiko","family":"Nakajima","sequence":"first","affiliation":[{"name":"Molecular Imaging and Therapy Service, Department of Radiology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison J.","family":"Moskowitz","sequence":"first","affiliation":[{"name":"Lymphoma Service, Division of Hematologic Oncology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Michaud","sequence":"first","affiliation":[{"name":"Molecular Imaging and Therapy Service, Department of Radiology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3236-6093","authenticated-orcid":false,"given":"Audrey","family":"Mauguen","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9036-9463","authenticated-orcid":false,"given":"Connie Lee","family":"Batlevi","sequence":"first","affiliation":[{"name":"Lymphoma Service, Division of Hematologic Oncology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-5256","authenticated-orcid":false,"given":"Ahmet","family":"Dogan","sequence":"first","affiliation":[{"name":"Hematopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5170-4185","authenticated-orcid":false,"given":"Heiko","family":"Sch\u00f6der","sequence":"first","affiliation":[{"name":"Molecular Imaging and Therapy Service, Department of Radiology,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,4,28]]},"reference":[{"issue":"14","key":"2020042811385121200_B1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"issue":"5","key":"2020042811385121200_B2","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2020042811385121200_B3","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"issue":"27","key":"2020042811385121200_B4","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020042811385121200_B5","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular Lymphoma International Prognostic Index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"21","key":"2020042811385121200_B6","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin\u2019s disease. International Prognostic Factors Project on Advanced Hodgkin\u2019s Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"issue":"3","key":"2020042811385121200_B7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11899-016-0318-1","article-title":"PET scans for staging and restaging in diffuse large B-cell and follicular lymphomas","volume":"11","author":"Barrington","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"issue":"9759","key":"2020042811385121200_B8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"14","key":"2020042811385121200_B9","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"2020042811385121200_B10","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi [published correction appears in J Clin Oncol. 2014;32(10):1095]","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol"},{"issue":"31","key":"2020042811385121200_B11","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","volume":"37","author":"Bachy","year":"2019","journal-title":"J Clin Oncol"},{"issue":"36","key":"2020042811385121200_B12","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2012.42.4036","article-title":"Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography\/computed tomography-staged treatment-naive patients with Hodgkin lymphoma","volume":"30","author":"El-Galaly","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020042811385121200_B13","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00259-014-2706-x","article-title":"Characterizing bone marrow involvement in Hodgkin\u2019s lymphoma by FDG-PET\/CT","volume":"41","author":"Weiler-Sagie","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"2020042811385121200_B14","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2967\/jnumed.116.184218","article-title":"Prognostic value of bone marrow tracer uptake pattern in baseline PET scans in Hodgkin lymphoma: results from an international collaborative study","volume":"58","author":"Zwarthoed","year":"2017","journal-title":"J Nucl Med"},{"issue":"9","key":"2020042811385121200_B15","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1093\/annonc\/mdy250","article-title":"Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18","volume":"29","author":"Voltin","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"2020042811385121200_B16","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/ajh.23730","article-title":"Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma","volume":"89","author":"Adams","year":"2014","journal-title":"Am J Hematol"},{"issue":"8","key":"2020042811385121200_B17","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2967\/jnumed.112.114710","article-title":"In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET\/CT provides better diagnostic performance and prognostic stratification than does biopsy","volume":"54","author":"Berthet","year":"2013","journal-title":"J Nucl Med"},{"issue":"1","key":"2020042811385121200_B18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2012-12-473389","article-title":"PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement","volume":"122","author":"Khan","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2020042811385121200_B19","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2967\/jnumed.113.134486","article-title":"Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma","volume":"55","author":"Cerci","year":"2014","journal-title":"J Nucl Med"},{"issue":"3","key":"2020042811385121200_B20","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14071","article-title":"(18) F-FDG PET-CT and trephine biopsy assessment of bone marrow involvement in lymphoma","volume":"174","author":"Ujjani","year":"2016","journal-title":"Br J Haematol"},{"issue":"27","key":"2020042811385121200_B21","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"2020042811385121200_B22","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"issue":"3","key":"2020042811385121200_B23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/MNM.0000000000000059","article-title":"The value of semiquantitative analysis in identifying diffuse bone marrow involvement in follicular lymphoma","volume":"35","author":"El-Najjar","year":"2014","journal-title":"Nucl Med Commun"},{"issue":"9","key":"2020042811385121200_B24","doi-asserted-by":"crossref","first-page":"e2910","DOI":"10.1097\/MD.0000000000002910","article-title":"The value of PET\/CT in detecting bone marrow involvement in patients with follicular lymphoma","volume":"95","author":"Perry","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"2020042811385121200_B25","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/annonc\/mdl014","article-title":"18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading","volume":"17","author":"W\u00f6hrer","year":"2006","journal-title":"Ann Oncol"},{"issue":"8","key":"2020042811385121200_B26","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/annonc\/mdt137","article-title":"The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi","volume":"24","author":"Luminari","year":"2013","journal-title":"Ann Oncol"},{"key":"2020042811385121200_B27","unstructured":"Gerds\n              TA\n            \n          . prodlim: product-limit estimation for censored event history analysis. R package version 2018.04.18. Available at: https:\/\/CRAN.R project.org\/package=prodlim. Accessed 16 March 2020."},{"issue":"9","key":"2020042811385121200_B28","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2016.0117","article-title":"NCCN guidelines insights: non-Hodgkin\u2019s lymphomas, version 3.2016","volume":"14","author":"Horwitz","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"issue":"23","key":"2020042811385121200_B29","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1158\/1078-0432.CCR-13-1120","article-title":"A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine-tositumomab","volume":"19","author":"Press","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2020042811385121200_B30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2020042811385121200_B31","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/bloodadvances.2019032136","article-title":"Impact of age on clinical risk scores in follicular lymphoma","volume":"3","author":"Alig","year":"2019","journal-title":"Blood Adv"}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2020002956","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T00:00:00Z","timestamp":1596672000000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/8\/1812\/1725479\/advancesadv2020001579.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/8\/1812\/1725479\/advancesadv2020001579.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T15:40:54Z","timestamp":1588088454000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/8\/1812\/454562\/Baseline-FDGPETCT-detects-bone-marrow-involvement"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,28]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,4,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001579","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/bloodadvances.2020002956","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,28]]}}}